Our research found that the expression levels of six immune checkpoint inhibitors (B7-H3, CTLA4, LAG3, PD-1, PD-L1, and TIM3) were increased with the increase in MELK expression, and significant positive correlations have been found between MELK and these immune checkpoints in glioma. This evidence concerns the gene CD276 and central nervous system cancer.